| Literature DB >> 32775289 |
Azhar H Al-Kuraishi1, Salah D Al-Windy1, Hayder M Al-Kuraishy1, Ali I Al-Gareeb1.
Abstract
BACKGROUND: Acute toxoplasmosis (AT) which is caused by Toxoplasma gondii (T. gondii) leads to induction of pro-inflammatory and/or oxidative stress changes through activation of host immune response. Therefore, the endeavor of the present study was to assess endothelial dysfunction(ED) and oxidative stress in patients with acute toxoplasmosis.Entities:
Keywords: Endothelial dysfunction; Toxoplasma gondii; endothelin-1
Year: 2020 PMID: 32775289 PMCID: PMC7365500 DOI: 10.4103/tp.TP_26_19
Source DB: PubMed Journal: Trop Parasitol ISSN: 2229-5070
Demographic characteristics of the present study
| The characteristics | Control ( | Patients ( | |
|---|---|---|---|
| Age (years) | 31.78±9.28 | 33.67±8.41 | 0.45 |
| Gender (male:female ratio) | 6:14 | 4:27 | - |
| Male | 4 (20) | 4 (12.90) | 0.50 |
| Female | 14 (70) | 27 (87.09) | 0.13 |
| Marital status | |||
| Married | 11 (78.57) | 21 (77.78) | 0.94 |
| Unmarried | 3 (21.43) | 6 (22.21) | 0.93 |
| History of recurrent abortion | 1 (7.14) | 18 (66.67) | 0.0001* |
| History of contact with animals | 13 (65.00) | 25 (80.64) | 0.21 |
| Smoking | 7 (35.00) | 3 (9.68) | 0.02† |
| Associated diseases | |||
| Hypertension | - | 9 (29.03) | - |
| Asthma | - | 3 (9.67) | - |
| Dyslipidemia | - | 8 (25.80) | - |
| Peptic ulcer | - | 3 (9.67) | - |
| Current therapy | |||
| Aspirin | 6 (30.00) | 14 (45.16) | 0.28 |
| Theophylline | - | 3 (9.67) | - |
| Statins | - | 8 (25.80) | - |
| Lansoprazole | - | 3 (9.67) | - |
| IgM positive | - | 31 (100) | - |
| IgG positive | 3 (15.00) | 28 (90.32) | 0.0001* |
| Anti-toxoplasmosis agents | |||
| Spiramycin | - | 8 (25.80) | - |
| Clindamycin | - | 23 (74.19) | - |
Data presented as mean±SD, n, %, *P<0.01, †P<0.05. SD: Standard deviation, IgM: Immunoglobulin M, IgG: Immunoglobulin G
Changes in the immunoglobulin levels, pro-inflammatory, and oxidative stress biomarkers in patients with acute toxoplasmosis
| Variables | Control ( | Patients ( | 95% CI | |
|---|---|---|---|---|
| IgM (g/L) | 1.2±0.8 | 3.6±2.99 | 1.0213-3.778 | 0.001* |
| IgG (g/L) | 4.31±2.95 | 22.96±9.57 | 10.1073-19.192 | 0.0001* |
| IgA (g/L) | 1.99±1.34 | 4.72±2.54 | 1.4877-3.9723 | 0.0001* |
| IL-6 (pg/mL) | 1.88±0.51 | 3.22±1.61 | 0.5912-2.088 | 0.0007* |
*P<0.01. IL-6: Interluekin-6, CI: Confidence interval, IgM: Immunoglobulin M, IgG: Immunoglobulin G, IgA: Immunoglobulin A
Figure 1Biomarkers of endothelial dysfunction and oxidative stress in acute toxoplasmosis compared with the healthy controls
Correlations of immunoglobulin M levels with immunoglobulin levels, pro-inflammatory, and oxidative stress biomarkers in patients with acute toxoplasmosis
| Variables | Control ( | Patients ( |
|---|---|---|
| IgG (g/L) | 0.26, 0.26 | 0.55, 0.001* |
| IgA (g/L) | 0.22, 0.35 | 0.57, 0.0008* |
| IL-6 (pg/mL) | 0.19, 0.42 | 0.45, 0.01† |
| ET-1 (pg/mL) | 0.28, 0.23 | 0.51, 0.003* |
| MDA (nmol/mL | 0.20, 0.39 | 0.85, 0.0001* |
*P<0.01, †P<0.05. r: Correlation, P: Significant level, IL-6: Interluekin-6, ET-1: Endothelin, MDA: Malondialdehyde, IgG: Immunoglobulin G, IgA: Immunoglobulin A